# Glucocorticoids Combined with Methotrexate in the Treatment of Psoriasis Merged with Bullous Pemphigoid: A Case Report and Literature Review

**Authors:** Weimin Ma, Cheng Li, Haijun Miao

PMC · DOI: 10.1002/ccr3.72173 · Clinical Case Reports · 2026-02-28

## TL;DR

Combining glucocorticoids and methotrexate effectively treats psoriasis with bullous pemphigoid, reducing steroid use while maintaining remission.

## Contribution

This case report introduces a steroid-sparing treatment regimen for a rare psoriasis complication.

## Key findings

- Combined glucocorticoid and methotrexate therapy rapidly controls disease progression.
- The treatment achieves sustained remission while minimizing long-term steroid use.
- Long-term monitoring is necessary to manage potential recurrence during steroid tapering.

## Abstract

For psoriatic patients who develop bullous pemphigoid, a rare yet serious complication, prompt initiation of combined glucocorticoid and methotrexate provides rapid disease control and sustained remission. This regimen serves as an effective steroid‐sparing strategy, though long‐term monitoring remains essential to manage recurrence risks during steroid taper.

## Linked entities

- **Chemicals:** methotrexate (PubChem CID 4112)
- **Diseases:** psoriasis (MONDO:0005083), bullous pemphigoid (MONDO:0019082)

## Full-text entities

- **Genes:** IL17A (interleukin 17A) [NCBI Gene 3605] {aka CTLA-8, CTLA8, IL-17, IL-17A, IL17, ILA17}, MMP9 (matrix metallopeptidase 9) [NCBI Gene 4318] {aka CLG4B, GELB, MANDP2, MMP-9}, COL17A1 (collagen type XVII alpha 1 chain) [NCBI Gene 1308] {aka BA16H23.2, BP180, BPA-2, BPAG2, ERED, JEB4}, CD79A (CD79a molecule) [NCBI Gene 973] {aka IGA, IGAlpha, MB-1, MB1}
- **Diseases:** lesion (MESH:D009059), drug allergy (MESH:D004342), Psoriasis (MESH:D011565), erythema (MESH:D004890), parakeratosis (MESH:D010241), fever (MESH:D005334), Psoriatic lesion (MESH:D015535), immune dysregulation (OMIM:614878), bullous systemic lupus erythematosus (MESH:D008180), pruritus (MESH:D011537), autoimmune blistering diseases (MESH:D001768), Inflammatory (MESH:D007249), skin injury (MESH:D000069836), erythematous plaques (MESH:D003773), infection (MESH:D007239), eosinophilia (MESH:D004802), hyperkeratosis (MESH:D017488), toxicity (MESH:D064420), BP (MESH:D010391), erosions (MESH:D014077)
- **Chemicals:** steroid (MESH:D013256), Methylprednisolone (MESH:D008775), Methotrexate (MESH:D008727), Nicotinamide (MESH:D009536), folic acid (MESH:D005492), Halometasone (MESH:C036518)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12949393/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12949393/full.md

## References

20 references — full list in the complete paper: https://tomesphere.com/paper/PMC12949393/full.md

---
Source: https://tomesphere.com/paper/PMC12949393